SB-408124
Based on 1 Customer Validation
SB-408124 is a non-peptide OX1 receptor antagonist with Kis of 57 nM and 27 nM in whole cell and membrane, respectively. SB-408124 exhibits 50-fold selectivity over OX2 receptor.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.93%
- CAS 番号: 288150-92-5
- 分子式: C19H18F2N4O
- 分子量:356.37
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Orexin Receptor (OX Receptor) アイソフォーム固有の製品をすべて表示
More
生物活性
|
OX1 Receptor 57 nM (Ki, in whole cell ) |
OX1 Receptor 27 nM (Ki, in cell membrane) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 288150-92-5
-
性状 Solid
-
分子量 356.37
-
分子式 C19H18F2N4O
-
Color White to off-white
-
SMILES
O=C(NC1=CC(C)=NC2=C(C=C(C=C21)F)F)NC3=CC=C(C=C3)N(C)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
DMSO : 50 mg/mL (140.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Langmead CJ, et al. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol. 2004;141(2):340-346. [Content Brief]
[2]. Kis GK, et al. The osmotically and histamine-induced enhancement of the plasma vasopressin level is diminished by intracerebroventricularly administered orexin in rats. Pflugers Arch. 2012;463(4):531-536. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8061 mL | 14.0304 mL | 28.0607 mL | 70.1518 mL |
| 5 mM | 0.5612 mL | 2.8061 mL | 5.6121 mL | 14.0304 mL | |
| 10 mM | 0.2806 mL | 1.4030 mL | 2.8061 mL | 7.0152 mL | |
| 15 mM | 0.1871 mL | 0.9354 mL | 1.8707 mL | 4.6768 mL | |
| 20 mM | 0.1403 mL | 0.7015 mL | 1.4030 mL | 3.5076 mL | |
| 25 mM | 0.1122 mL | 0.5612 mL | 1.1224 mL | 2.8061 mL | |
| 30 mM | 0.0935 mL | 0.4677 mL | 0.9354 mL | 2.3384 mL | |
| 40 mM | 0.0702 mL | 0.3508 mL | 0.7015 mL | 1.7538 mL | |
| 50 mM | 0.0561 mL | 0.2806 mL | 0.5612 mL | 1.4030 mL | |
| 60 mM | 0.0468 mL | 0.2338 mL | 0.4677 mL | 1.1692 mL | |
| 80 mM | 0.0351 mL | 0.1754 mL | 0.3508 mL | 0.8769 mL | |
| 100 mM | 0.0281 mL | 0.1403 mL | 0.2806 mL | 0.7015 mL |